2m 2m 2m 2m 2m 2m 2m
ANI Pharmaceutic (ANIP)
NASDAQ
$83.65+$0.70 (+0.85%)
Price as of Jun 23, 2026 5:36 PM EDT- $1.8BMarket Cap
- 23.83%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
ANI Pharmaceutic (ANIP)
$83.65+$0.70 (+0.85%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 883.4M +43.78% | 614.4M +26.20% | 486.8M +53.87% | 316.4M +46.38% | |
Cost of Revenue | 341.3M +36.41% | 250.2M +37.85% | 181.5M +30.79% | 138.8M +37.94% | |
Gross Profit | 542.1M +48.85% | 364.2M +19.28% | 305.3M +71.90% | 177.6M +53.73% | |
Sales and Marketing Expense | 317.7M +27.28% | 249.6M +54.39% | 161.7M +30.35% | 124.0M +47.16% | |
Research and Development Expense | -51.7M +15.89% | -44.6M +30.03% | -34.3M +53.62% | -22.3M +96.31% | |
Depreciation and Amortization Expense | 91.4M +34.97% | 67.7M +13.28% | 59.8M +0.23% | 59.7M +26.24% | |
Total Operating Expenses | 772.3M +25.82% | 613.8M +39.55% | 439.8M +25.07% | 351.7M +37.41% | |
Operating Profit | 111.1M +18,922.77% | 584,000 -98.76% | 47.0M +233.13% | -35.3M -11.33% | |
Interest Income | 12.5M -21.99% | 16.0M N/A | N/A N/A | N/A N/A | |
Interest Expense | -20.1M +13.96% | -17.6M -34.66% | -26.9M -3.96% | -28.1M +135.30% | |
Interest Income and Expense and Net | -7.6M +379.57% | -1.6M -94.15% | -26.9M -3.96% | -28.1M +135.30% | |
Total Nonoperating Income and Expense | 1.9M +147.95% | -4.0M +2,436.48% | -159,000 -123.73% | 670,000 +115.43% | |
Income before Taxes | 95.8M +531.26% | -22.2M -211.78% | 19.9M +131.71% | -62.7M +11.79% | |
Income Taxes | 17.5M +573.01% | -3.7M -437.60% | 1.1M +107.40% | -14.8M +9.77% | |
Extraordinary Items | 767,000 -89.91% | 7.6M N/A | 0 -100.00% | 574,000 -75.82% | |
Net Income | 78.3M +522.94% | -18.5M -198.63% | 18.8M +139.21% | -47.9M +12.42% | |
Net Income from Continuing Operations Applicable to Common | 77.2M +483.08% | -20.1M -217.45% | 17.2M +134.64% | -49.5M +15.72% | |
Basic EPS and Net Income | 3.50 +436.54% | -1.04 -220.93% | 0.86 +128.20% | -3.05 -10.29% | |
Diluted EPS and Net Income | 3.32 +419.23% | -1.04 -222.35% | 0.85 +127.87% | -3.05 -10.29% | |
Basic Weighted Average Shares | 20.1M +3.80% | 19.3M +7.32% | 18.0M +10.71% | 16.3M +29.09% | |
Diluted Weighted Average Shares | 21.2M +9.89% | 19.3M +6.18% | 18.2M +11.89% | 16.3M +29.09% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 285.6M +97.14% | 144.9M -34.49% | 221.1M +358.49% | 48.2M -51.92% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 285.6M +97.14% | 144.9M -34.49% | 221.1M +358.49% | 48.2M -51.92% | |
Total Current Assets | 753.1M +42.72% | 527.7M +1.51% | 519.8M +50.99% | 344.3M +6.99% | |
Accumulated Depreciation | 52.7M +17.40% | 44.9M +36.27% | 32.9M +0.68% | 32.7M +42.50% | |
Property and Plant and Equipment and Net | 62.5M +9.87% | 56.9M +27.52% | 44.6M +3.11% | 43.2M -17.89% | |
Total Long-Term Assets | 13.7M +12.16% | 12.2M +1.23% | 12.1M +6.26% | 11.4M +415.24% | |
Total Assets | 1.4B +12.21% | 1.3B +41.94% | 904.4M +18.99% | 760.1M -1.49% | |
Income Taxes Payable | 1.3M -80.87% | 6.7M -17.33% | 8.2M N/A | N/A N/A | |
Total Short-Term Debt | 17.3M +88.27% | 9.2M +979.06% | 850,000 0.00% | 850,000 0.00% | |
Total Current Liabilities | 278.1M +43.59% | 193.7M +33.13% | 145.5M +46.30% | 99.4M +13.60% | |
Total Long-Term Debt | 291.8M -5.59% | 309.1M +8.53% | 284.8M -0.30% | 285.7M -0.30% | |
Total Long-Term Liabilities | 12.2M +110.41% | 5.8M +20.21% | 4.8M +248.23% | 1.4M -82.30% | |
Total Liabilities | 899.7M +5.20% | 855.2M +91.39% | 446.8M +6.00% | 421.5M +2.10% | |
Retained Earnings | -23.1M -76.97% | -100.3M +25.14% | -80.1M -17.63% | -97.3M +103.68% | |
Total Stockholders Equity | 540.7M +33.95% | 403.7M -6.72% | 432.7M +37.95% | 313.7M -6.05% | |
Total Shares Outstanding | 22.5M -64.72% | 63.7M +55.60% | 41.0M +17.07% | 35.0M +3.75% | |
Cash Flow | |||||
Cash from Operating Activities | 185.2M +189.34% | 64.0M -46.19% | 119.0M +481.24% | -31.2M -1,039.28% | |
Capital Expenditures | 13.8M -14.79% | 16.2M +83.09% | 8.9M -0.09% | 8.9M +247.13% | |
Cash from Investing Activities | -34.3M -91.52% | -404.7M +2,086.37% | -18.5M +17.62% | -15.7M -85.08% | |
Dividends Paid | 1.2M -28.80% | 1.6M 0.00% | 1.6M 0.00% | 1.6M +755.26% | |
Cash from Financing Activities | -9.9M -103.75% | 264.9M +292.87% | 67.4M +1,415.63% | -5.1M -102.63% | |
Financials Ratio | |||||
Gross Margin | 61.36% +3.52% | 59.27% -5.49% | 62.71% +11.72% | 56.13% +5.02% | |
Operating Margin | 12.58% +13,124.08% | 0.10% -99.01% | 9.65% +186.52% | -11.15% -39.43% | |
Return on Assets | 5.75% +439.72% | -1.69% -175.03% | 2.26% +136.08% | -6.25% -9.52% | |
Return on Equity | 16.59% +474.59% | -4.43% -188.02% | 5.03% +134.01% | -14.79% -8.06% | |
Revenue Growth | 43.78% +67.09% | 26.20% -51.36% | 53.87% +16.14% | 46.38% +1,162.17% | |
Current Ratio | 2.71 -0.61% | 2.72 -23.75% | 3.57 +3.21% | 3.46 -5.82% | |
Cash Ratio | 1.03 +37.30% | 0.75 -50.80% | 1.52 +213.40% | 0.49 -57.67% | |
Debt-to-Equity Ratio | 0.57 -27.49% | 0.79 +19.44% | 0.66 -27.73% | 0.91 +6.12% | |
Debt-to-Assets Ratio | 0.21 -13.43% | 0.25 -21.53% | 0.32 -16.21% | 0.38 +1.24% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow